Note de episod
BNTC stock analysis: 100% clinical response signals massive upside — deep dive
👉 Want this level of research on ANY COMPANY IN THE WORLD... for FREE? Check us out at: https://flash.stocksentinel.ai/?utm_source=rss_podcast&utm_medium=podcast&utm_campaign=freja_and_friends
In this deep dive, we break down Benitec Biopharma Inc. (BNTC) and its breakthrough "Silence and Replace" gene therapy platform following 100% responder rates in Phase 1b/2a clinical trials for OPMD. With shares trading near $8.70 against an enterprise value of $140.8M backed by $176.5M in cash, the key question for…
Site: flash.stocksentinel.ai

